Clinical trials: Digestive System Cancer
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Colorectal Neoplasms
Colorectal Cancer RECHALLENGE
Primary Objective: To demonstrate that re-challenge with an oxaliplatin based regimen (modified FOLFOX-6) will provide a clinical disease control rate (DCR) of at least 20% at the end of the chemotherapy.
- Trial name
- NCT00988897
- Testing
- OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV)
- Where
- Canada
- Sponsor
- Sanofi
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie
Gastrointestinal Tumors, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06755242
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Cancer
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with 5-fluorouracil, folinic Acid, and oxaliplatin (mFOLFOX6) in participants with…
- Trial name
- NCT01662869
- Testing
- 5-Fluoruracil, Folinic acid, Onartuzumab
- Where
- 125 sites in United States, Australia and 22 more
- Volunteers
- 564 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor prognosis with progression-free survival of around…
- Trial name
- NCT01580397
- Testing
- INNO-206
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Colon Cancer, Colorectal Carcinoma
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
This study evaluates the efficacy, safety and tolerability of NER1006 versus Trisulfate Solution (TS) in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning…
- Conditions
- Colon Cancer, Colorectal Carcinoma, Colon Cleansing
- Trial name
- NOCT (NCT02254486)
- Testing
- NER1006, Trisulfate solution
- Where
- 12 sites in United States
- Volunteers
- 621 people
- Sponsor
- Norgine
Esophageal Squamous Cell Carcinoma
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT07700667
- Testing
- SKB500, Tislelizumab, Cisplatin
- Where
- 24 sites in China
- Volunteers
- 120 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Duodenal Obstruction, Gastric Outlet Obstruction
EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms
The objective of this investigation is to compile clinical experience on the use of the Evolution® Duodenal Stent (Cook Ireland), a CE marked device intended for the palliative treatment of duodenal or gastric outlet obstruction…
- Trial name
- NCT00991614
- Testing
- EVOLUTION® Duodenal Stent
- Where
- 6 sites in Australia, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Cook Group Incorporated
Cancer, PDAC
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations.
- Conditions
- Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
- Trial name
- NCT07198321
- Testing
- GFH276
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Hepatocellular Carcinoma
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Trial name
- NCT02314052
- Testing
- DCR-MYC
- Where
- 6 sites in United States, Singapore and 1 more
- Volunteers
- 21 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Gastrointestinal Neoplasms, Postoperative Complications
The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients
The study is designed to investigate the influence of parenteral nutrition (PN) with low nitrogen and calorie supply on the clinical outcome of patients after an operation compared to that of traditional PNs.
- Trial name
- NCT00247338
- Testing
- low calorie, low nitrogen parenteral nutrition for patient with NRS score 3
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sino-Swed Pharmaceutical Corporation
Gastrointestinal Cancer
To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer
This is a prospective, randomized, open label, active-controlled, multi-centre, non-inferiority clinical trial. Aim of the study is to evaluate the efficacy and safety of Fresubin Support Drink in patients with gastrointestinal…
- Trial name
- NCT05606848
- Testing
- Nutrition Emulsion (TPF-T), Foods for special medical purposes [FSMP] for patients with tumors
- Where
- 14 sites in China
- Volunteers
- 350 people
- Sponsor
- Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM)…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Lymphoma Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT01435525
- Where
- 36 sites in Japan
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Carcinoma, Hepatocellular
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Open-label, uncontrolled, Phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
- Trial name
- NCT03897543
- Testing
- ABX196
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Abivax S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.